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Macrophages regulate the clearance
of living cells by calreticulin
Dmitri V. Krysko 1,2, Kodi S. Ravichandran3,4,5 & Peter Vandenabeele 4,5,6
Recently, Feng, Weissman and colleagues demonstrated that activated macrophages secrete
calreticulin (CRT), which binds to the surface of viable target cells and marks them for removal
by programmed cell phagocytosis (PrCP)1. CRT is one of the ‘eat me’ signals, which is often
thought to localize in the lumen of the endoplasmic reticulum (ER), but was also found on the
plasma membrane of apoptotic cancerous cells (Fig. 1), where it is believed to function as an ‘eat
me’ signal2 and a damage-associated molecular pattern (DAMP) responsible for the immuno-
genicity of apoptotic cancerous cells3. Remarkably, some viable cells also expose CRT but are
apparently protected from engulfment. One of the mechanisms for this protection is related to
repelling signals mediated by so-called ‘don’t eat me’ signals concurrently expressed on the cells,
such as CD31, CD200 and CD474. Importantly, clearance of viable cells has been recently
recognized in a few contexts, and it has been intriguing, in part due to the lack of an obvious
mechanism, and also for its relevance. Some examples of reported live cell clearance include
suicidal emperipolesis5, entosis6, phagoptosis7, and cell cannibalism8. However, the source and
speciﬁc role of CRT in the engulfment of viable cells and the binding moiety on the surface of
viable cells have not been known yet.
Feng et al. showed that activated macrophages are a source of CRT bound on the surface of
neutrophils. In order to distinguish between efferocytosis9 of apoptotic neutrophils versus the
uptake of CRT-marked ‘live’ or ‘aged’ neutrophils by PrCP, the authors performed a comparison
between wild type and Bcl-2-overexpressing neutrophils and conﬁrmed a 25-old report from the
same group that the eventual extent of uptake is not affected by blocking apoptosis in the target
cells10. However, although several mechanisms of CRT exposure on the surface of cells
undergoing immunogenic apoptosis have been described11, which mechanisms of CRT secretion
are used by macrophages to enhance PrCP are currently unknown and many more interesting
and challenging ﬁndings are expected. In this regard it has also been suggested the links between
ER calcium depletion and detection of ER-resident proteins, including CRT, in the extracellular
space12.
What does the CRT bind to on the surface of neutrophils and possibly other viable cells
engulfed via PrCP? Since CRT is involved in the quality control of glycoproteins in the ER by a
lectin-like function, the authors asked whether during PrCP, the extracellular binding of CRT on
neutrophils (and other living cells) may also involve sugar moieties. Feng et al. found that CRT
selectively bound to asialoglycans displaying the Tri-antennary and multivalent type II chain
epitopes (Tri/m-II). This speciﬁcity of CRT-binding was conﬁrmed on mature murine neu-
trophils, as well as on the cell surface of a viable human acute myeloid leukemia cell line (HL60)
and a human colon cancer cell line (SW620) by competitive binding with Phytohaemagglutinin-
L (PHA-L), a lectin with the same speciﬁcity for Tri/m-II1. These ﬁndings demonstrate that this
CRT binding and speciﬁcity can be extended to other cell types than neutrophils and suggest that
PrCP could be a general phenomenon that may occur during different biological processes such
as inﬂammation resolution and anti-cancer surveillance (Fig. 1).
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Neuraminidase is a glycoside hydrolase that removes sialic
acids from the terminal positions of glycans and exposes the
cryptic Tri/m-II, leading to increased CRT binding. Having
identiﬁed the asialoglycan epitope involved in CRT binding, the
authors then examined whether CRT-binding and PrCP could be
modulated by neuraminidase treatment1. They found that this
treatment signiﬁcantly promoted PrCP of different types of viable
human cancer cells by both human and mouse macrophages. In a
complementary approach, Feng et al. found that knocking out the
neuraminidase-4 gene (neu-4) in a cancer cell line, signiﬁcantly
decreased PrCP. To test the potential usefulness of these obser-
vations to clinical settings, the authors mined transcriptome
databases of cancers and this revealed higher expression of genes
promoting the removal of sialic acids (such as neuraminidases)
correlated with an improved survival, while higher expression of
the genes enhancing sialic acid expression (such as sialyl trans-
ferases) correlated with a worse outcome. Also, during normal
and pathological haematopoiesis the level of CRT or PHA-L
binding correlated inversely with cellular half-life, with highest
binding in blast cells and lowest in multipotent progenitors,
leukemia stem cells and haematopoeitic stem cells. These studies
indicate that regulation of asialoglycan levels on the cell surface
and the subsequent PrCP due to the CRT mediated recognition
could be important during homeostasis and inﬂammation reso-
lution and as well as immunosurveilance.
This work by Feng et al. reveals several new pieces of infor-
mation and as all good studies, also raises a number of questions.
First, previous studies have suggested that CRT on the surface of
apoptotic cells functions as a (DAMP responsible for the
immunogenicity of apoptotic cancerous cells3,13,14. This current
work places CRT in a new context, i.e. in the clearance of ‘viable’
cancer cells with CRT acting as an ‘eat me’ signal. Whether
modulation of the asialoglycan epitope by neuraminidase treat-
ment also modulate the uptake of apoptotic cells, whether this
will modulate their immunogenicity is a question that could also
be relevant for tumor immunotherapy. In this regard, Feng et al.
showed that neuraminidase treatment leads to a decrease in
tumor engraftment and growth in mice, and that in humans,
stronger expression of genes enhancing sialic acids expression
correlates with a worse outcome1. Future studies addressing the
anti-tumor responses could be useful. This raises also the ques-
tion whether other phagocytic cells, such dendritic cells, can
secrete CRT to decorate their preys, and whether engulfment of
viable cancer cells would lead to antigen presentation. Second, the
current work suggesting the modulation of asialoglycoproteins on
the surface of viable cells and the section of CRT from macro-
phages, begin to provide mechanistic insights. Although not
focus of this work, whether different types of tissue macrophages
as well as their differentiation (such as M1-like versus M2-like
signatures) might alter CRT secretion, or whether the PrCP is
rather a feature of tumor associated macrophages remain to be
seen. Finally, beyond tumor immunosurveillance, an intriguing
observation is the interaction between viral neurominidases (such
as Inﬂuenza virus) and the host cells. Indeed Inﬂuenza neuro-
minidases have been shown to enhance phagocytosis of
Inﬂuenza-infected cells through desialylation15. Future investi-
gations will lead to a better understanding of the molecular
mechanisms of the clearance of viable cells during cancer and
viral infections with relevance to anti-tumor therapies as well as
normal hematopoietic development.
Received: 10 July 2018 Accepted: 20 September 2018
References
1. Feng, M. et al. Programmed cell removal by calerticulin in tissue homeostasis
and cancer. Nat. Commun. 9, 3194 (2018).
2. Gardai, S. J. et al. Cell-surface calreticulin initiates clearance of viable or
apoptotic cells through trans-activation of LRP on the phagocyte. Cell 123,
321–334 (2005).
3. Galluzzi, L., Buque, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunogenic
cell death in cancer and infectious disease. Nat. Rev. Immunol. 17, 97–111
(2017).
4. Chao, M. P., Majeti, R. & Weissman, I. L. Programmed cell removal: a new
obstacle in the road to developing cancer. Nat. Rev. Cancer 12, 58–67 (2011).
Macrophage
Viable cells
Apoptotic
cell
sCRT
Viable
cell
Asialoglycoproteins
Sialic acids
Neuraminidase Cell death
inducers  
Phagocytosis
PS
CD47
Macrophage
CD91
PS receptors
mCRT
a b
CD47
Fig. 1 Mechanisms of recognition of viable (a) and apoptotic (b) cells. a A soluble calreticulin (sCRT) secreted by activated macrophages is capable of
binding to asialoglycans on viable target cells, depending on their developmental or damage state, which in turn, marks them for uptake. Neuraminidase-4
is one enzyme that could be involved in the generation of cell surface asialoglycans that bind sCRT. The cell-surface mCRT on the target cells can now
interact with CD91, which is also known as low-density lipoprotein receptor-related protein 1 (LRP1). b CRT and CD91 have also been linked to
immunogenic apoptotic cell death. On the surface of apoptotic cells expose phosphatidylserine (PS) and mCRT that function as “eat me” signals. The
mCRT expression is particularly linked to cell death induced by agents that are known to induce immunogenic forms of apoptotic cell death. The expression
of “don’t eat me” signals (e.g., CD47) on the apoptotic cells is either reduced or its location modiﬁed. Many membrane-bound receptors for PS have been
reported, including those that bind PS directly or indirectly via bridging molecules. mCRT can bind CD91 on the phagocyte. The authors thank Servier for
the ﬁgures that were produced using Servier Medical Art (www.servier.com)
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